The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Mélissa Carbonneau(Hôpital Maisonneuve-Rosemont), Frédérick A. Mallette(Hôpital Maisonneuve-Rosemont), Marc‐Étienne Huot(Centre hospitalier de l'Université Laval), Anthony Tumber(University of Oxford), Udo Oppermann(Oxford BioMedica (United Kingdom)), Mathieu Laplante(PROTEO), Russell G. Jones(Van Andel Institute), Laurence M. Gagné(Université Laval), Marie-Anne Germain(Hôpital Maisonneuve-Rosemont), Alena Motorina(Hôpital Maisonneuve-Rosemont), Blandine Secco(Institut universitaire de cardiologie et de pneumologie de Québec), Jonathan Bergeman, Emma E. Vincent(University of Bristol), Laura Hulea(Hôpital Maisonneuve-Rosemont), Marie‐Christine Guiot(McGill University), Ivan Topisirović(Jewish General Hospital), Marie‐Eve Lalonde(Hôpital Maisonneuve-Rosemont), Kevin Petrecca(McGill University Health Centre)
Cited by 179
Related Papers
mTOR signaling at a glance
|Journal of Cell Science|2009|2.1k
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation
|Cell Metabolism|2016|1.5k
Tumor suppressors and cell metabolism: a recipe for cancer growth
|Genes & Development|2009|1.1k
Medium- and short-chain dehydrogenase/reductase gene and protein families
|Cellular and Molecular Life Sciences|2008|903
A roadmap for interpreting 13C metabolite labeling patterns from cells
|Current Opinion in Biotechnology|2015|652